Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2898336 | Cardiology Clinics | 2008 | 7 Pages |
Abstract
Over the last 15 years, a series of well-designed randomized clinical trials has clearly demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces mortality in select high-risk populations. Despite the widespread acceptance of ICD therapy, many questions related to its optimal use remain. This article discusses several key issues now confronting clinicians.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Pamela K. Mason, John P. DiMarco,